Abstract
Background A thrombogenic potential metric was used to compare prosthetic valve models in vitro.
Methods Valves were tested in aortic and mitral sites under pulsatile circulation in a pulse duplicator. An optical approach measures dynamic valve area. Pulsatile fluid dynamics were measured by conventional techniques and a quasi-steady flow tester was used to measure valve leakage. Regurgitant flow velocity was derived using time-dependent volumetric flow rate / dynamic valve area. Since flow velocity and fluid shear force are related through flow velocity gradient, thrombogenic potential for valves that achieve near closure during the forward flow deceleration phase were determined as regurgitant flow velocities relative to the control mechanical valve regurgitant flow velocity of −126 m/s. Analysis of the flow velocity data made use of Vioplot R* and VISIO software packages to provide split violin plots that represent probability of recurrence of data.
Results Thrombogenic potential was made dimensionless and ranged between −0.45 and +1.0. Negative thrombogenic potentials arise when transient rebound of valve occluder is accompanied by water-hammer phenomena. Positive thrombogenic potentials occur during decelerating forward flow. Bioprostheses had lowest thrombogenic potential transient of 0.15. A mock-transcatheter aortic valve replacement incorporating by design a trivial paravalvular leak (∼1.35 ml/s) demonstrated a high transient thrombogenic potential of 0.95.
Conclusions Our data reveals distinct thrombogenic potential profile differences between valve models. If our study methods are verifiable, the design of future valves may utilize currently available experimental tools to produce advanced devices with significantly reduced thrombogenic potential.
Highlights
➢ Prosthetic valve shortcomings include chronic unresolved thrombogenicity and durability issues.
➢ Thrombogenic potential of mechanical valves is fueled by brief, high closing flow velocities.
➢ Trivial leakage in bioprosthetic valves can yield high thrombogenic potential.
➢ Valve motion and flow velocity metrics may help advance prosthetic valve designs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been done on a pro bono basis by all authors with no financial support of others.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Footnotes
Conflict of interest statement: None declared.
Sources of funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
All data relevant to the study are included in the article or uploaded as supplementary information.
Abbreviations and Acronyms (minimized)
- BHV
- bioprosthetic heart valve
- BV3D
- rapid prototype bileaflet mechanical valve (3D printed)
- HITS
- high intensity trancranial signal
- ml/s
- milliliters per second
- m/s
- meters per second
- ms
- milliseconds
- mTAVR
- mock-transcatheter aortic valve replacement
- MHV
- mechanical heart valve
- PDVA
- projected dynamic valve area
- PVL
- paravalvular leakage
- RFV
- regurgitant flow velocity
- s
- second
- SJM
- St Jude Medical
- TP
- thrombogenic potential
- VIA
- viscoelastic impedance adapter
